<DOC>
	<DOCNO>NCT02969746</DOCNO>
	<brief_summary>This prospective , multicentric , randomize , open label superiority trial This study aim evaluate efficacy oral activate charcoal improve elimination direct oral anticoagulant ( Rivaroxaban , Dabigatran , Apixaban ) case unscheduled invasive procedure delay anticoagulant treatment . The primary outcome anticoagulant 's half life . Plasma concentration measure liquid chromatography-mass spectrometry main analysis ( pharmacokinetic ) Pharmacodynamics also determine specific anti-Xa level ( Rivaroxaban / Apixaban ) dilute thrombin time ( Dabigatran ) . A total 72 patient randomly assign charcoal control group , stratify accord anticoagulant drug .</brief_summary>
	<brief_title>Activates Charcoal Patients Undergoing Invasive Procedure Delayed Due Direct Oral Anticoagulants</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Patients direct oral anticoagulant treatment ( Apixaban , Rivaroxaban Dabigatran ) Age â‰¥18 year ; Clinical condition need surgery invasive procedure ( lumbar puncture , biopsy ... ) , need anticoagulant treatment interruption intervention postpone Signed inform consent Urgent immediate surgery without possibility wait 24 hour contraindication receive oral treatment Active uncontrolled bleed bleed critical organ Hemodynamic instability , shock Known anticoagulant concentration &lt; 50ng/mL drug intoxication Fructose intolerance , glucose galactose malabsorption syndrome , sucraseisomaltase deficit Treated epileptic disease Pregnant breast feed Patient guardianship No insurance cover Patient unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>activate charcoal , direct oral anticoagulant</keyword>
</DOC>